within Pharmacolibrary.Drugs.ATC.R;

model R03AC15
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0013333333333333333,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AC15</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Reproterol is a short-acting β2-adrenoceptor agonist used for the treatment of asthma and other pulmonary diseases. It is employed as a bronchodilator and is most commonly administered by inhalation or intravenously in acute asthma attacks. Its use is currently approved in some countries but not widely available in all regions.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available for reproterol; all values below are estimates extrapolated from general knowledge of similar short-acting β2-agonists and limited product information for typical adult patients.</p><h4>References</h4><ol><li><p>Niebch, G, et al., &amp; Thiemer, K (1977). [Studies on pharmacokinetics and biotransformation of reproterol in animal and man (author&#x27;s transl)]. <i>Arzneimittel-Forschung</i> 27(12) 37–45. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/576829/\">https://pubmed.ncbi.nlm.nih.gov/576829</a></p></li><li><p>Hageman, RJ, et al., &amp; Koëter, GH (1988). Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. <i>Biopharmaceutics &amp; drug disposition</i> 9(3) 301–314. DOI:<a href=\"https://doi.org/10.1002/bod.2510090308\">10.1002/bod.2510090308</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3395671/\">https://pubmed.ncbi.nlm.nih.gov/3395671</a></p></li><li><p>Kucharczyk, N, et al., &amp; Sofia, RD (1981). Biotransformation of reproterol in the intestinal tract of the rat. <i>Arzneimittel-Forschung</i> 31(12) 2085–2088. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7199302/\">https://pubmed.ncbi.nlm.nih.gov/7199302</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AC15;
